Evidence map›Paper›PMID 29285211›Full record

ArticleOncotarget2017

Molecular analyses of prostate tumors for diagnosis of malignancy on fine-needle aspiration biopsies.

Menglin Shan, Qianlin Xia, Dong Yan, Yanjun Zhu, Xuan Zhang, Guihong Zhang, Jianming Guo, Jun Hou, Weiping Chen, Tongyu Zhu and 5 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 2 countries.

Menglin Shan *Shanghai Public Health Clinical Center, Fudan University, Jinshan, Shanghai, P.R. China.
Qianlin Xia *Shanghai Public Health Clinical Center, Fudan University, Jinshan, Shanghai, P.R. China.
Dong Yan *Department of Medical Oncology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, P.R. China.
Yanjun Zhu *Department of Urology, Zhongshan Hospital, Fudan University, Yangpu, Shanghai, P.R. China.
Xuan ZhangShanghai Public Health Clinical Center, Fudan University, Jinshan, Shanghai, P.R. China.
Guihong ZhangShanghai Public Health Clinical Center, Fudan University, Jinshan, Shanghai, P.R. China.
Jianming GuoDepartment of Urology, Zhongshan Hospital, Fudan University, Yangpu, Shanghai, P.R. China.
Jun HouPathology, Zhongshan Hospital, Fudan University, Yangpu, Shanghai, P.R. China.
Weiping ChenGenomics Core, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Tongyu ZhuShanghai Public Health Clinical Center, Fudan University, Jinshan, Shanghai, P.R. China.
Xiaoyan ZhangShanghai Public Health Clinical Center, Fudan University, Jinshan, Shanghai, P.R. China.
Jianqing XuShanghai Public Health Clinical Center, Fudan University, Jinshan, Shanghai, P.R. China.
Jin WangShanghai Public Health Clinical Center, Fudan University, Jinshan, Shanghai, P.R. China.
Tao DingDepartment of Urology, The Sixth People's Hospital South Campus, Shanghai Jiao Tong University, Fengxian, Shanghai, P.R. China.
Jianghua ZhengShanghai Public Health Clinical Center, Fudan University, Jinshan, Shanghai, P.R. China.
Shanghai Public Health Clinical Center · CNCapital Medical University · CNFudan University · CNNational Institute of Diabetes and Digestive and Kidney Diseases · USShanghai Jiao Tong University · CNShanghai University of Medicine and Health Sciences · CNZhongshan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) is a common cancer and remains the second-leading cause of cancer-associated mortality in men, but diagnosis of PCa remains a main clinical challenge. To investigate the involvement of differentially expressing genes in PCa with deregulated pathways to allow earlier diagnosis of the disease, transcriptomic analyses of differential expression genes in fine-needle aspiration (FNA) biopsies helped to discriminate PCa from benign prostatic hyperplasia (BPH). We identified 255 genes that were deregulated in prostate tumors compared with BPH tissues. qRT-PCR was conducted to examine the expression levels of the four genes in FNA biopsies and confirmed that ITGBL1 was significantly up-regulated and HOXA7, KRT15 and TGM4 were down-regulated in the PCa compared to the BPH, with a sensitivity of 87.1% and a specificity of 87.8%; the area under the receiver operating characteristic curve was estimated at 0.94, which was significantly improved compared with PSA alone (AUC = 0.82). Moreover, the increased expression of ITGBL1 correlated with total cholesterol, triglyceride and PSA. Our results demonstrated that transcriptomic analyses in FNA biopsies could facilitate rapid identification of potential targets for therapy and diagnosis of PCa.

Indexed as

fine-needle aspirationgene expression profilingpathway analysisprostate cancer

Identifiers

PMID29285211
PMCPMC5739598
OpenAlexW2767694090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.